Dr Joe Yeong

Group Leader, Institute of Molecular and Cell Biology (IMCB, A*STAR, Singapore)

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of cancer immunotherapy. As an immunopathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of multiplex IHC/IF, using clinical autostainers to translate assays to clinic, and has published > 120 papers in the field. His works on cancer immunology are included in multiple National funded studies as well as pharmaceutical industry sponsored projects (>15 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 & 2023 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also having editorial roles of Nature Springer (Scientific Report), Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers, Pathogens and World Scientific (Chief Editor). He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre. In 2023, he co-founded World Immunotherapy Council Asian Chapter for promoting tumor immunology and advancing cancer immunotherapy education, information and research across Asia.